DUPIXENT had a demonstrated safety profile in VESTIGE3

TEAEs occurring in ≥5% of DUPIXENT + SOC patients and at a higher rate than placebo + SOC in VESTIGEg

DUPIXENT + SOC
(n=72) n (%)

COVID-19

7 (10)

Injection site reactionf

4 (6)

Placebo + SOC (n=37) n (%)

COVID-19

3 (8)

Injection site reactionf

1 (3)

gThe safety population includes all randomized patients who received at least one dose of DUPIXENT.

OLE, open-label extension; SOC, standard of care; TEAE, treatment-emergent adverse event.